ReviewActa pharmaceutica Sinica. B2023
The feasibility of oral targeted drug delivery: Gut immune to particulates?
Review in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances and challenges in research methods on oral absorption mechanisms of nano-formulations.PeerJ · 2025Pooled it
- Oral self-assembly nanoemulsion drivesDrug delivery · 2026Article
- Polystyrene nanoplastics induce size-associated oxidative-inflammatory stress, hepatic insulin-signaling impairment and metabolic disturbances in normal and diabetic mice.Biology direct · 2026Article
- Separation and Characterization of Self-Assembled Nanoparticles fromAntioxidants (Basel, Switzerland) · 2026Article
- From bench to bowel: translating targeted drug delivery through gastrointestinal barriers.Frontiers in bioengineering and biotechnology · 2026Review
- Microneedle Innovations in Oral Therapeutics: Transforming Protein and Peptide Delivery.AAPS PharmSciTech · 2025Review
- Microfluidics-on-a-chip for designing celecoxib-based amorphous solid dispersions: when the process shapes the product.Drug delivery and translational research · 2025Article
- Recent Advances in Propranolol Hydrochloride Formulations for the Treatment of Infantile Hemangiomas.Drug design, development and therapy · 2025Review
- Nanometerizing Taxifolin Into Selenized Liposomes to Ameliorate Its Hypoglycemic Effect by Optimizing Drug Release and Bioavailability.International journal of nanomedicine · 2025Article
- HIV Tat as a latency reversing agent: turning the tables on viral persistence.Frontiers in immunology · 2025Review
- Solubilization techniques used for poorly water-soluble drugs.Acta pharmaceutica Sinica. B · 2024Review
- Fabrication of Luteolin Nanoemulsion by Box-Behnken Design to Enhance its Oral Absorption Via Lymphatic Transport.AAPS PharmSciTech · 2024Article
- Oral In-Situ Nanoplatform with Balanced Hydrophobic-Hydrophilic Property for Transport Across Gastrointestinal Mucosa.AAPS PharmSciTech · 2024Article
- Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.Pharmaceutics · 2024Review
- Advanced hybrid silica nanoparticles with pH-responsive diblock copolymer brushes: optimized design for controlled doxorubicin loading and release in cancer therapy.RSC advances · 2024Article
- Cellular Uptake and Transport Mechanism Investigations of PEGylated Niosomes for Improving the Oral Delivery of Thymopentin.Pharmaceutics · 2024Article
- Enteral Route Nanomedicine for Cancer Therapy.International journal of nanomedicine · 2024Review
- Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted drug delivery is constantly updated with a better understanding of the physiological and pathological features of various diseases. Depending on high safety, good compliance and many other undeniable advantages, attempts have been undertaken to complete an intravenous-to-oral conversion of targeted drug delivery. However, oral delivery of particulates to systemic circulation is highly challenging due to the biochemical aggressivity and immune exclusion in the gut that restrain absorption and access to the bloodstream. Little is known about the feasibility of targeted drug delivery
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.